Insuman Comb 15 (Insulin Human (Rdna))

Insulin human mimics the action of naturally occurring insulin. It binds to insulin receptors on muscle, fat and liver cells, activating intracellular pathways that increase glucose uptake, promote glycogen synthesis, and suppress hepatic glucose production, thereby lowering circulating blood‑glucose concentrations.

The dose of Insuman Comb 15 is individualized. A qualified prescriber determines the total daily insulin requirement based on the patient’s blood‑glucose profile, body weight, diet, activity level and renal or hepatic function. Dose titration is performed under medical supervision.

Safety data for insulin human in pregnancy and lactation are limited. Insulin is generally considered the preferred glucose‑lowering agent when needed during pregnancy, but the prescriber must weigh potential benefits against any unknown risks and monitor maternal and fetal health closely.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Insuman Comb 15. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and required import documentation.

Insuman Comb 15 contains human insulin, which has a slower onset and longer duration compared with rapid‑acting insulin analogues such as insulin lispro or aspart. It is less expensive and widely used for basal coverage, while analogues may offer more flexible dosing schedules and reduced risk of nocturnal hypoglycaemia.

Insuman Comb 15 must be stored refrigerated between 2 °C and 8 °C. Keep the vial in its original carton, protect it from light, and avoid freezing. Once in use, the solution may be kept at room temperature (up to 25 °C) for a limited period, typically 28 days, as indicated on the label.

Insuman Comb 15 is administered by subcutaneous injection into the abdomen, thigh or upper arm using a sterile needle or pen device. The injection site should be rotated to minimise lipodystrophy. Patients should be trained on proper technique, needle disposal and timing relative to meals.

The most serious risks include severe hypoglycaemia that can lead to loss of consciousness or seizures, and allergic reactions ranging from local rash to anaphylaxis. Prompt recognition and treatment of these events are essential, and patients should be instructed to seek immediate medical attention if they occur.

Insuman Comb 15 is contraindicated in individuals with a known hypersensitivity to human insulin or any of the excipients in the formulation. It should also be avoided in patients with severe hypoglycaemia unresponsive to treatment until the underlying cause is resolved.